Michael Burkes Brophy Sells 25,931 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07. Following the sale, the chief financial officer now directly owns 109,665 shares of the company’s stock, valued at approximately $18,091,435.05. This trade represents a 19.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The stock was sold at an average price of $118.81, for a total value of $82,097.71.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $171.82 on Friday. Natera, Inc. has a 1-year low of $62.96 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business has a fifty day moving average price of $165.35 and a 200-day moving average price of $135.41. The company has a market capitalization of $22.68 billion, a PE ratio of -97.63 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period last year, the company earned ($0.95) earnings per share. The company’s revenue was up 63.9% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several large investors have recently bought and sold shares of the business. Farallon Capital Management LLC increased its holdings in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares in the last quarter. Wellington Management Group LLP increased its holdings in Natera by 205.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock worth $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after buying an additional 85,236 shares in the last quarter. Geode Capital Management LLC increased its holdings in Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after buying an additional 143,825 shares in the last quarter. Finally, Duquesne Family Office LLC increased its holdings in Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after buying an additional 45,500 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NTRA shares. Morgan Stanley raised their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their price target on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Canaccord Genuity Group raised their price objective on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.